Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NNG.WA
Strong SellSinkerNanoGroup S.A. · Healthcare · Poland · $28M · Avg Vol: $27K/d
COMPANY DESCRIPTION
NanoGroup S.A. is a Polish biotechnology company focused on the research, development, and commercialization of advanced nanotechnology-based medical products and drug delivery systems. The company's proprietary nanocarrier platforms aim to revolutionize oncology treatments and organ transplantation preservation. As an early-stage innovator, NanoGroup holds a robust intellectual property portfolio targeting high-value, unmet global medical needs.
FINANCIAL SUMMARY (PLN)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 0.5M | 0.1M | 2.0K | 2.1K | 0 | -83.8% | 8.0K |
| EPS (PLN) | -0.25 | -0.02 | -0.18 | -0.16 | -0.29 | — | -0.29 |
| Shares | 42.6M | 42.6M | 42.6M | 31.6M | 32.8M | -23.0% | 42.6M |
| Debt | 0.3M | 0.1M | 0 | 0 | 0 | -51.2% | — |
| Equity | 7.7M | 7.1M | 4.5M | 15.2M | 8.7M | 3.0% | — |
| Op CF | -2.7M | -3.7M | -4.8M | -5.7M | -8.8M | — | -8.9M |
| Inv CF | -3.9M | -0.8M | -3.7M | -4.6M | -13.3M | — | — |
| Fin CF | 0.7M | 3.0M | 6.5M | 17.6M | 29.7M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NNG.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NNG.WA | NanoGroup S.A.(you) | $28M | 14 | Strong Sell |
| PTG.WA | Poltreg S.A. | $34M | 13 | Strong Sell |
| MOC.WA | Molecure S.A. | $40M | 14 | Strong Sell |
| MAB.WA | Mabion S.A. | $34M | 10 | Strong Sell |
| URT.WA | Urteste S.A. | $18M | 12 | Strong Sell |
| SVE.WA | Synthaverse S.A. | $46M | 11 | Strong Sell |
| MQR.WA | MultiQure S.A. | $10M | 3 | Strong Sell |
| BCX.WA | Bioceltix S.A. | $118M | 18 | Strong Sell |
| PUR.WA | Pure Biologics S.A. | $8M | 3 | Strong Sell |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $120M | 6 | Strong Sell |
Peer medians: ROE -16.3% · P/E 17.0x · Gross margin 30.1%